SCHEMBL572199

SCHEMBL572199

O=C1CNc2ccccc2C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.63
HSD17B10 Q99714 1/20 0.63
CYP1A2 P05177 1/20 0.52
AHR P35869 1/20 0.52
PDK2 Q15119 1/20 0.52
CYP2A6 P11509 1/20 0.45
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NPC1 O15118 2/20 0.42
MAPT P10636 2/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
HSP90AA1 P07900 1/20 0.42
THRB P10828 1/20 0.42
HK1 P19367 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2510066 0.83 NPC1 (0.55) ALOX15HSD17B10CYP1A2AHRPDK2
Hydrochloric Acid SCHEMBL6137385 0.81 NPC1 (0.53) ALOX15HSD17B10CYP1A2AHRPDK2
SCHEMBL4391893 0.79 CYP2A6 (0.52) ALOX15HSD17B10CYP1A2AHRPDK2
SCHEMBL8805855 0.79 BRPF1 (0.47) ALOX15HSD17B10CYP1A2AHRPDK2
SCHEMBL2087881 0.77 ALOX15 (1.00) ALOX15HSD17B10CYP1A2AHRPDK2
SCHEMBL31546300 0.77 ALOX15 (1.00) ALOX15HSD17B10CYP1A2AHRPDK2
SCHEMBL30668800 0.76
SCHEMBL2041999 0.76
SCHEMBL1828551 0.76
SCHEMBL5193435 0.74 ALOX15 (0.57) ALOX15HSD17B10AHRPDK2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109293493-A With the inhibition active novel benzhydryl class compound of mycobacterium tuberculosis 清华大学 2019-02-01 CN claimed
CN-103772276-B 2-[6-methoxyl group-3-(2,3-dichlorophenyl) methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1 (4H)-quinolyl] preparation method of acetic acid SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2016-05-11 CN claimed
CN-103772276-A Preparation method of 2-(6-methoxy-3-(2, 3-dichlorophenyl) methyl-4-oxo-1, 4-dihydro-1(4H)-quinolyl) acetic acid UNIV SHENYANG PHARMACEUTICAL 2014-05-07 CN claimed
CN-101723893-A 2,3-disubstituted-2,3-dihydro quinoline ketone chiral compound as well as preparation method and application thereof SHANGHAI INST ORGANIC CHEM 2010-06-09 CN claimed
US-10000535-B2 Template-fixed peptidomimetics POLYPHOR LTD. (CH) 2018-06-19 US disclosed
CN-105418497-B The synthesis technique of 3 chlorine octahydro 2 (1H) quinolinones 大连鼎燕医药化工有限公司 2018-04-17 CN disclosed
CN-103772276-B 2-[6-methoxyl group-3-(2,3-dichlorophenyl) methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1 (4H)-quinolyl] preparation method of acetic acid SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2016-05-11 CN disclosed
CN-103772276-B 2-[6-methoxyl group-3-(2,3-dichlorophenyl) methyl-4-oxo-Isosorbide-5-Nitrae-dihydro-1 (4H)-quinolyl] preparation method of acetic acid SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2016-05-11 CN disclosed
CN-105418497-A Synthesis technology of 3-chloro-octahydro-2(1H)-quinolinone DALIAN DINGYAN MEDICINE CHEMICAL CO LTD 2016-03-23 CN disclosed
US-20160046625-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC (US) 2016-02-18 US disclosed
US-9115127-B2 Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase AMGEN INC. (US) 2015-08-25 US disclosed
EP-2600874-B1 PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE AMGEN INC (US) 2015-03-04 EP disclosed
US-5696133-A ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-09 US disclosed
US-5693647-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 US disclosed
US-5693646-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 US disclosed
US-5688808-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 US disclosed
US-5688810-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 US disclosed
EP-0800519-A1 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 1997-10-15 EP disclosed
CN-1150799-A Benzoheterocyclic derivatives OTSUKA PHARMA CO LTD (JP) 1997-05-28 CN disclosed
WO-1996019458-A2 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 1996-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160046625-A1 BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE BCL6, DCK, FLI1 ALOX15 3658/4885HSD17B10 1208/4885CYP1A2 1226/4885
US-10000535-B2 Template-fixed peptidomimetics CCR10, CXCR3, CCR5 ALOX15 4255/4885HSD17B10 2492/4885CYP1A2 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.